ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)

被引：0

作者：

Susanna Slater

Annette Bryant

Hsiang-Chi Chen

Ruwaida Begum

Isma Rana

Maria Aresu

Clare Peckitt

Oleg Zhitkov

Retchel Lazaro-Alcausi

Victoria Borja

Rachel Powell

David Lowery

Michael Hubank

Thereasa Rich

Gayathri Anandappa

Ian Chau

Naureen Starling

David Cunningham

机构：

[1] Royal Marsden Hospital NHS Foundation Trust,

[2] Biomedical Research Centre at the Royal Marsden and the Institute of Cancer Research,undefined

[3] Centre for Molecular Pathology at the The Royal Marsden Hospital and Institute of Cancer Research,undefined

[4] Guardant Health,undefined

[5] INC,undefined

来源：

BMC Cancer | / 23卷

关键词：

Colorectal cancer; ctDNA; Adjuvant chemotherapy; Randomised; Disease free survival;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 48 条

[21] Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial [J].

Yamazaki, K. ;

Yamanaka, T. ;

Shiozawa, M. ;

Manaka, D. ;

Kotaka, M. ;

Gamoh, M. ;

Shiomi, A. ;

Makiyama, A. ;

Munemoto, Y. ;

Rikiyama, T. ;

Fukunaga, M. ;

Ueki, T. ;

Shitara, K. ;

Shinkai, H. ;

Tanida, N. ;

Oki, E. ;

Sunami, E. ;

Ohtsu, A. ;

Maehara, Y. ;

Yoshino, T. .

ANNALS OF ONCOLOGY, 2021, 32 (01) :77-84

[22] The Effect of Vitamin D Supplementation on Quality of Life in Stage II-III Colorectal Cancer Patients Undergoing Adjuvant Chemotherapy: A Single-Blind, Randomized Controlled Trial [J].

Perinandika, Tovan ;

Rudiman, Reno ;

Purnama, Andriana .

JOURNAL OF GASTROINTESTINAL CANCER, 2025, 56 (01)

[23] Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JS']JSWOG-C2 study [J].

Tsuruta, Atsushi ;

Yamashita, Kazuki ;

Tanioka, Hiroaki ;

Tsuji, Akihito ;

Inukai, Michio ;

Yamakawa, Toshiki ;

Yamatsuji, Tomoki ;

Yoshimitsu, Masanori ;

Toyota, Kazuhiro ;

Yamano, Taketoshi ;

Nagasaka, Takeshi ;

Okajima, Masazumi .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 :3827-3835

[24] Model-based evaluation of the cost effectiveness of 3versus6 months' adjuvant chemotherapy in high-risk stage II colon cancer patients [J].

Jongeneel, Gabrielle ;

Greuter, Marjolein J. E. ;

van Erning, Felice N. ;

Koopman, Miriam ;

Vink, Geraldine R. ;

Punt, Cornelis J. A. ;

Coupe, Veerle M. H. .

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13

[25] Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study [J].

Kexuan Li ;

Fuqiang Zhao ;

Yuchen Guo ;

Qingbin Wu ;

Shuangling Luo ;

Junling Zhang ;

Heli Li ;

Shidong Hu ;

Bin Wu ;

Guole Lin ;

Huizhong Qiu ;

Beizhan Niu ;

Xiyu Sun ;

Lai Xu ;

Junyang Lu ;

Xiaohui Du ;

Zheng Wang ;

Xin Wang ;

Liang Kang ;

Ziqiang Wang ;

Quan Wang ;

Qian Liu ;

Yi Xiao .

BMC Cancer, 23 (1)

[26] A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC) [J].

Oki, E. ;

Murata, A. ;

Yoshida, K. ;

Maeda, K. ;

Ikejiri, K. ;

Munemoto, Y. ;

Sasaki, K. ;

Matsuda, C. ;

Kotake, M. ;

Suenaga, T. ;

Matsuda, H. ;

Emi, Y. ;

Kakeji, Y. ;

Baba, H. ;

Hamada, C. ;

Saji, S. ;

Maehara, Y. .

ANNALS OF ONCOLOGY, 2016, 27 (07) :1266-1272

[27] Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study [J].

Li, Kexuan ;

Zhao, Fuqiang ;

Guo, Yuchen ;

Wu, Qingbin ;

Luo, Shuangling ;

Zhang, Junling ;

Li, Heli ;

Hu, Shidong ;

Wu, Bin ;

Lin, Guole ;

Qiu, Huizhong ;

Niu, Beizhan ;

Sun, Xiyu ;

Xu, Lai ;

Lu, Junyang ;

Du, Xiaohui ;

Wang, Zheng ;

Wang, Xin ;

Kang, Liang ;

Wang, Ziqiang ;

Wang, Quan ;

Liu, Qian ;

Xiao, Yi .

BMC CANCER, 2023, 23 (01)

[28] Risk Factors for Peritoneal Recurrence in Stage II/III Gastric Cancer Patients Who Received S-1 Adjuvant Chemotherapy After D2 Gastrectomy [J].

Toru Aoyama ;

Takaki Yoshikawa ;

Tsutomu Hayashi ;

Hiroshi Kuwabara ;

Yo Mikayama ;

Takashi Ogata ;

Haruhiko Cho ;

Akira Tsuburaya .

Annals of Surgical Oncology, 2012, 19 :1568-1574

[29] Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6 [J].

Laurent, Marie ;

Guetz, Gaetan Des ;

Bastuji-Garin, Sylvie ;

Culine, Stephane ;

Caillet, Philippe ;

Aparicio, Thomas ;

Audureau, Etienne ;

Carvahlo-Verlinde, Muriel ;

Reinald, Nicoleta ;

Tournigand, Christophe ;

Landre, Thierry ;

LeThuaut, Aurelie ;

Paillaud, Elena ;

Canoui-Poitrine, Florence .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01) :73-80

[30] Factors predicting the response to oral fluoropyrimidine drugs: A phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study) [J].

Mori, Takeo ;

Ohue, Masayuki ;

Takii, Yasumasa ;

Hashizume, Tadashi ;

Kato, Tomoyuki ;

Kotake, Kenjiro ;

Sato, Toshihiko ;

Tango, Toshiro .

ONCOLOGY REPORTS, 2013, 29 (02) :437-444

← 1 2 3 4 5 →